Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

48P - The A2AR antagonist inupadenant promotes humoral responses in preclinical models

Date

12 Dec 2024

Session

Poster Display session

Presenters

Paola Tieppo

Citation

Annals of Oncology (2024) 24 (suppl_1): 1-16. 10.1016/iotech/iotech100742

Authors

P. Tieppo1, M. Mercier1, S. Jung1, D. Carbonez1, L. Chaible1, R. Marillier1, F. Strozzi1, M. Dieu-Nosjean2, H. Shehade1, Y. McGrath3, M. Rossetti3

Author affiliations

  • 1 iTeos Therapeutics, Gosselies/BE
  • 2 INSERM U1135, UMRS1135 Sorbonne Université, Paris/FR
  • 3 iTeos Therapeutics, 6041 - Gosselies/BE

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 48P

Background

A2A receptor (A2AR) is a key mediator of adenosine immunosuppression. Inupadenant is a highly selective A2AR antagonist, which maintains full potency at the high levels of adenosine found in tumors. We recently reported that B cells are a novel cellular target of inupadenant (Martinoli et al., AACR 2023). Here, we further investigate how inupadenant modulates humoral responses in vitro, ex vivo and in vivo.

Methods

Inupadenant was assessed through: in vitro generation of antibody secreting cells (ASCs) from memory B cells isolated from human PBMCs; ex vivo tumor culture of tumor slices derived from human lung cancer; and single cell RNA sequencing (scRNAseq) on isolated healthy tonsil B cells. The A2AR agonist CGS-21680 (in vitro and scRNAseq) or ATP (ex vivo) were added to trigger A2AR signaling, and B cells were stimulated with CpG (scRNAseq) or CD40L (ex vivo). Cell cultures were assessed by flow cytometry and Legendplex. The CT26-OVA model was used to study tumor-targeted immunoglobulin (Ig) production and immune infiltration by ELISA and RNAseq.

Results

Inupadenant rescued the A2AR-mediated inhibition of B cell maturation into ASCs and Ig production in both in vitro and ex vivo systems. In CT26-OVA mice, inupadenant increased OVA-specific IgGs in blood and tumor, as well as B cells and ASCs in spleen and tumor. Besides ASCs, germinal center (GC) B cells were the main B cell subset affected by A2AR signaling in human tonsil, as supported by (i) the highest number of differentially expressed genes observed in these subsets after CGS-21680 stimulation, and (ii) by their highest expression of the A2AR gene, ADORA2A. Inupadenant completely reverted the effect of CGS-21680 in ASCs and GC B cells, including the expression of AICDA, a critical gene for somatic hypermutation and class-switch recombination in GCs.

Conclusions

These data support the notion that inupadenant restores or even potentiates B cell maturation toward ASCs and GC reactions in both secondary lymphoid organs as well as tumor in the presence of A2AR signaling. This process is essential to produce high affinity antibodies and potentially for sustained anti-tumor immunity. Additional work is ongoing to confirm this novel mechanism in inupadenant-treated patients.

Legal entity responsible for the study

iTeos Therapeutics.

Funding

iTeos Therapeutics.

Disclosure

P. Tieppo, M. Mercier, S. Jung, D. Carbonez, L. Chaible, R. Marillier, F. Strozzi, H. Shehade, Y. McGrath, M. Rossetti: Financial Interests, Personal, Full or part-time Employment: iTeos Therapeutics; Financial Interests, Personal, Stocks/Shares: iTeos Therapeutics. M. Dieu-Nosjean: Financial Interests, Personal, Speaker, Consultant, Advisor: iTeos Therapeutics.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.

  • Analytics cookies help us improve our website by collecting and reporting information on its usage.

  • We use marketing cookies to build a profile of you as a user through your actions on our site in order to better understand your interests and provide you with pertinent suggestions.